Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Feb 23;4(3):229-231.
doi: 10.1016/j.jdcr.2017.09.028. eCollection 2018 Apr.

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma

Liezel L Griffin  1 , Laura Cove-Smith  2   3 , Hana Alachkar  4 , John A Radford  2   3 , Rebecca Brooke  1 , Kim M Linton  2   3
Affiliations
Case Reports

Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma

Liezel L Griffin et al. JAAD Case Rep. .
No abstract available

Keywords: PD-1, programmed death-1 protein; TEN, toxic epidermal necrolysis; adverse events; immune related; irAEs, immune-related adverse events; lymphoma; nivolumab; programmed death-1 inhibitor; toxic epidermal necrolysis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Toxic epidermal necrolysis. Erosions to the lower back.
Fig 2
Fig 2
Toxic epidermal necrolysis. Epidermal detachment and blistering to upper arm.
See this image and copyright information in PMC

References

    1. Rizvi N.A., Mazieres J., Planchard D. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265. - PMC - PubMed
    1. Brahmer J.R., Tykodi S.S., Chow L.Q.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. - PMC - PubMed
    1. Weber J.S., D'Angelo S.P., Minor D. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384. - PubMed
    1. Ansell S.M., Lesokhin A.M., Borrello I. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–319. - PMC - PubMed
    1. Creamer D., Walsh S.A., Dziewulski P. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174(6):1194–1227. - PubMed

Publication types

LinkOut - more resources